Please assess the completion status of the following clinical trial:

Trial Title: Chronic Effects of Euphytose® on Psychological and Physiological Measures of Stress

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 18-65 years~* In good physical health~* Subjects agree to abstain throughout the trial from all dietary supplements (note: protein shakes and garlic supplements are allowed)~* Body Mass Index above 18 kg/m2 and below 35 kg/m2~* Subjects are, in the opinion of the investigator, willing to participate in all scheduled visits and to adhere to all study procedures~* Subjects accept to refrain from alcohol intake 24 hours prior to Testing Visits 1-4~* Subjects do not have a current diagnosis of a significant medical condition which may interfere with the subject's ability to perform assessments and successfully completes training~* Subjects provide a personally signed and dated informed consent indicating that the subject has been informed of all pertinent aspects of the trial and understood and accepts these~* Have a bank account (required for payment)~Exclusion Criteria:~* Have any pre-existing medical condition/illness? NOTE: the exceptions to this are controlled (medicated) arthritis, asthma, high cholesterol and reflux-related conditions~* Event (personal or professional) likely to have impacted the subject's emotional and/ or psychological state within the last 8 weeks (for example but not restricted to: change of professional function/situation, death of a family member, divorce, surgery, accident, etc.)~* Event (personal or professional) likely to affect the subject's emotional, psychological or hormonal state planned during the next 8 weeks, including vaccination, important medical exam etc.~* Smoking or the use of any nicotine replacement products e.g. vaping, gum, patches (smoking within the last 3 months)~* Blood pressure \>159/99 millimeters of mercury (mmHg)~* Excessive use of caffeine (\> 500 mg caffeine per day) from all dietary sources~* Current intake of pharmaceuticals (excluding contraception and arthritis, cholesterol and reflux-related hormone replacement treatments (for female participants) where symptoms are stable and medications do not contraindicate the study outcomes and inhalers used as required)~* Have taken antibiotics within the last 4 weeks~* Any known active infections~* Have a recent history of (within 12 months of screening visit) or strong potential for alcohol or substance abuse. Alcohol abuse is defined as more than 60g (men) / 40g (women) pure alcohol per day (7 / 5.5 units)~* A history of neurological or psychiatric diseases excluding anxiety or depression~* A diagnosis/treatment for a psychiatric disorder within the past 12 months (including anxiety or depression)~* A history of significant head trauma~* Have sleep disturbances and/or are taking sleep aid medication~* Have learning difficulties or dyslexia~* Have visual impairment that cannot be corrected with glasses or contact lenses (including colour blindness)~* Have frequent migraines that require medication (more than or equal to 1 per month)~* Not proficient in English equivalent to International English Language Testing System (IELTS) band 6 or above~* Are pregnant, trying to get pregnant or breast feeding~* Have any health condition that would prevent fulfillment of the study requirements~* Any condition which may interfere with the subjects ability to perform assessments~* Are employed in a job that includes night shift work~* Have no access to the internet (including via smartphone)~* Are unable to perform the computerized tests during training to the established acceptable levels for participation in this type of study.~* Have habitually used supplements, within the last month (defined as more than 3 consecutive days or 4 days in total)~* Participation in another clinical trial within 30 days prior to screening~* Any history of hypersensitivity to the investigational product or its active or inactive constituents or any food allergy or intolerance~* Non-compliant in terms of treatment consumption

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Euphytose® (Type: ACTIVE_COMPARATOR): Euphytose® 2 tablets 3 times per day for 14 days
- Placebo (Type: PLACEBO_COMPARATOR): Matched placebo 2 tablets, 3 times per day for 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).